On page 295, Table 4 contains formatting errors. “Dermatitis atopic” should be indented and should not be in boldface type, and the last 4 rows of the table should be shaded. The corrected Table 4 is shown below.

Table 4.

Treatment-emergent IMAEs of any grade (in more than 2% of patients) or grade 3 or higher (all events)

Preferred termTotal (N = 57)
Any gradeGrade ≥3
Patients with any event, n (%)  19 (33) 8 (14) 
Hypothyroidism 5 (9) 
Pneumonitis 3 (5) 1 (2) 
Rash maculopapular 3 (5) 1 (2) 
Alanine aminotransferase increased 2 (4) 1 (2) 
Aspartate aminotransferase increased 2 (4) 1 (2) 
Dermatitis acneiform 2 (4) 
Rash 2 (4) 
Autoimmune hepatitis 1 (2) 1 (2) 
Colitis 1 (2) 1 (2) 
Dermatitis atopic 1 (2) 
Hypophysitis 1 (2) 1 (2) 
Rash morbilliform 1 (2) 1 (2) 
Transaminases increased 1 (2) 1 (2) 
Preferred termTotal (N = 57)
Any gradeGrade ≥3
Patients with any event, n (%)  19 (33) 8 (14) 
Hypothyroidism 5 (9) 
Pneumonitis 3 (5) 1 (2) 
Rash maculopapular 3 (5) 1 (2) 
Alanine aminotransferase increased 2 (4) 1 (2) 
Aspartate aminotransferase increased 2 (4) 1 (2) 
Dermatitis acneiform 2 (4) 
Rash 2 (4) 
Autoimmune hepatitis 1 (2) 1 (2) 
Colitis 1 (2) 1 (2) 
Dermatitis atopic 1 (2) 
Hypophysitis 1 (2) 1 (2) 
Rash morbilliform 1 (2) 1 (2) 
Transaminases increased 1 (2) 1 (2) 

One patient may have multiple events.

On page 296 in lines 2 and 4 of the paragraph beginning “Direct comparison,” the study number SWOGS186 should be SWOG S1826.

On page 298, reference 16 should cite a different National Comprehensive Cancer Network guideline publication. The reference should read as follows.

16. Hoppe RT, Advani RH, Ai WZ, et al. NCCN Guidelines® Insights: Hodgkin lymphoma, version 2.2022. J Natl Compr Canc Netw. 2022;20(4):322-334.

Sign in via your Institution